Heart attack survivors should avoid common painkillers.
New research featured on WEBMD from a Danish study suggests that heart attack survivors who use common pain relievers may have a higher risk of having another heart attack or dying. The study links non-steroidal anti-inflammatory drugs such as Celebrex, Aleve, Motron, and Voltaren to poorer outcomes with heart patients.
This is just another in a series of studies which recently suggests that the pain relivers should be used cautiously. The research does not categorically provide that NSAIDS are responsible for the events, however. Still, as Anne-Marie Schjerning Olsen, MD, who led the study says, "Our results indicate that use of NSAIDS is associated with persistently increased coronary risk, regardless of the time elapsed after a heart attack. Thus, long-term caution is advised in all patients."
According to the study, those patients who took NSAID pain relievers after a heart attack had a 59% increased risk of death from any cause within one year of having the attack, and a 63% increased risk over five years.
You can read the report here.
If you or a loved one feel you have suffered due to a medical misjudgement of any type, contact our office for a free consultation. Call us at (731) 423-1888 or (615) 371-6136.
MEDICAL RECALL for HEART DAMAGE TESTS
If you or a loved one underwent a heart test between June 29, 2011 and March 12, 2012 which included the use of these particular immunoassayies and lot numbers, you/they may have suffered serious health consequences as a result. Contact our office at (731) 423-1888 for information regarding how you may be entitled to compensation.
The FDA has issued a Class 1 RECALL for Roche Diagnostics biochemical tests Elecsys Troponin I and Elecsys Troponin I STAT Immunoassays (lot numbers 163176 and 163177) which were distributed between June 29, 2011 and January 13, 2012. Doctors who used these tests to determine heart damage (as an aid in the diagnosis of a heart attack) may have received a falsely low result and these incorrect results may have caused serious adverse health consequences, including death.
On March 12, 2012, Roche Diagnostics Operations sent an “URGENT MEDICAL DEVICE REMOVAL” letter to all its customers (doctors, clinics, laboratories & hospitals) who received the affected lots of Elecsys Troponin I or Elecsys Troponin I STAT. The letter described the product, problem, and actions to be taken. A Class 1 FDA recall is the most serious type of recall and involve situations in which there is a reasonable probability that use of these products would have caused serious consequences.
Start blogging by creating a new post. You can edit or delete me by clicking under the comments. You can also customize your sidebar by dragging in elements from the top bar.